[Hepatitis B vaccine. Assessment of vaccines obtained from human plasma].
This review addresses three questions: Why should HBV vaccines be used? Who should receive them? How should they be made and given? It is suggested that the major function of HBV vaccine, in addition to preventing acute hepatitis in high-risk groups, is prevention of chronic HBV infections (i.e., the HBV carrier state) particularly in high-prevalence regions, with their attendant eventual morbidity and mortality due to cirrhosis and hepatocellular carcinoma. Target populations for vaccine use, subject to vaccine availability, are defined in accordance with this concept. Existing approaches to vaccine manufacture are compared and discussed; all appear to provide safe and immunogenic vaccines. However, it is too early to draw conclusions as to their relative immunogenicity, efficacy, and economy.
D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000008:administration & dosage; D006512:Hepatitis B Core Antigens / Q000302:isolation & purification; D006513:Hepatitis B e Antigens / Q000302:isolation & purification; D006801:Humans; D007116:Immunization, Passive; D012306:Risk; D013997:Time Factors; D014611:Vaccination
D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D006513:Hepatitis B e Antigens
Hepatitis B-Vakzine Eine Bewertung der aus Humanplasma gewonnenen Impfstoffe.